American Journal of Biomedical Engineering

American Journal of Biomedical Engineering provides a forum for the publication of the latest developments in biomedical engineering, and reflects the essential multidisciplinary nature of the subject. The journal publishes in-depth critical reviews, scientific papers and technical notes.

Tamer Elbayoumi

Editorial Board Member of American Journal of Biomedical Engineering

Assistant Professor, Midwestern University-Glendale, USA

Research Areas

Targeted nanocarrier delivery systems for therapeutics and imaging agents, mainly including investigational nanomedicines for cardiovascular therapy, cancer chemotherapy and diagnostic imaging


2007Post Doct. FellowshipCenter of Pharmaceutical Biotechnology & Nanomedicine, Northeastern University, Boston, MA
2006Ph.D.Bouvé College of Health Sciences, School of Pharmacy, Northeastern University, Boston, MA
2003M.S.Bouvé College of Health Sciences, School of Pharmacy, Northeastern University, Boston, MA
1999B.S.Faculty of Pharmacy. Alexandria University, Alexandria


2009-presentAssistant Professor of Pharmaceutical Sciences; Midwestern University, College Pharmacy-Glendale, AZ
2006-presentAdjunct Pharmaceutical Scientist; Nour Heart, Inc., Edgewater, MD
2006-2009Senior Formulation Scientist; Cardiolvascular Systems, Atrium Medical Corp., Hudson, NH
2005-2006Post-Doctoral Research Associate; Northeastern University, Boston, MA
2003-2005Research Assistant of Advanced Drug Delivery; Northeastern University, Boston, MA
2002-2003Teaching Assistant of Pharmaceutics; Northeastern University, Boston, MA
1999-2001Research & Development Assistant-preformulation; Rhône-Poulenc Pharma, Alexandria, Egypt

Academic Achievement

2004 Beta Tau Chapter membership-National Rho Chi Pharmaceutical Honor Society (USA)
2006"Outstanding Parenteral Drug Delivery Award", Controlled Release Society (Austria)
2010 Theme guest co-editor for Journal of Drug Delivery, March, 2011, "Advances in Assessment of Pharmaceutical Nanocarriers"
2010 Scientific Contribution Award, medical Research Institute, University of Alexandria, Egypt
2011 Special theme issue guest co-editor for Journal of Membrane Science and Technology, July, 2011, "Nano & micro engineered membrane technology"
2011 Special theme issue primary guest editor for Journal of Membrane Science and Technology, September, 2011, "Liposome Technology"
2010-2012 Co-editor with V. Weissig, and M. Olsen, for Cellular and Subcellular Nanotechnology: Methods and Protocols, of Methods in Molecular Biology Ser. Humana Press, New Jersey, (contract signed, under production for 2012)


2008-present Pharmaceutical Consultant; Reuters Insight, Inc., of Thompson Reuters Stamford, CT
2004-present Member, Controlled Release Society, Inc., (CRS)
2006-present Member, Society for Biomaterials (SFB)
2005-present Member, American Association of Pharmaceutical Scientists (AAPS)
2008-present Member, American Chemical Society (ACS)
2009-presentMember, Parenteral Drug Association (PDA)
2009-presentMember, American Association of Colleges of Pharmacy (AACP)
2009-2010 NIH Peer Review Committee: special emphasis panel, ZRG1 OTC-K (58) R, Oncology-2 Translational Clinical IRG, ad hoc(mail) reviewer
2009-presentMember of the Editorial Review Board of the Journal of Membrane Science and Technology
2010-presentMember, American Association of Cancer Research (AACR)
2011-presentFounding chair of the AAPS SouthWest Regional Discussion Group (SWRDG: provisional)

Publications: Journals

[1]  A.Lukyanov†, T. Elbayoumi†, A.Chakilam, V,Torchilin, "Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody". Journal of Controlled Release, 2004;100(1):135-44. (†ANL&TAE equally contributed in this study)
[2]  L. Mu, T. Elbayoumi, V. Torchilin, "Mixed micelles made of polyethyleneglycol-phosphatidylethanolamine conjugate and D-α-tocopheryl polyethylene glycol 1000 succinate as carriers for camptothecin". International Journal of Pharmaceurics, 2005; 306 (1-2):142-9.
[3]  T. Elbayoumi and V. Torchilin, "Enhanced accumulation of long-circulating liposomes modified with nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: Gamma-imaging studies". European Journal of Nuclear Medicine and Molecular Imaging, 2006; 33(10):196-205.
[4]  T. Elbayoumi, S. Pabbas, A. Ruby, and V. Torchilin, "Anti-nucleosome antibody modified liposomes and lipid-core micelles for tumor targeted delivery of therapeutic and diagnostic agents". Journal of Liposome Research, 2007; 17(1):1-14.
[5]  T. Elbayoumi and V. Torchilin, "Internalization of anti-nucleosome antibody targeted Doxorubicin PEG-liposomes induces enhanced cytotoxicity against various tumour cell lines". European Journal of Pharmaceutical Sciences, 2007; 32(3):159-68.
[6]  T. Elbayoumi and V. Torchilin, "Tumor-specific antibody-mediated targeted delivery of Doxil® reduces the manifestation of auricular erythema side effect in mice". International Journal of Pharmaceutics, 2008; 357(1-2):272-9.
[7]  T. Elbayoumi and V. Torchilin, "Tumor-targeted immuno-liposomes for Cancer therapy and imaging" Journal of Pharmaceutical Innovations, 2008; (4):2-7.
[8]  T. Elbayoumi and V.Torchilin, "Liposomes for enhanced delivery of thrombolytic agents", Expert Opinion in Drug Delivery, 2008; 5(11):1185-98.
[9]  T. Elbayoumi and V. Torchilin, "Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice". Molecular Pharmaceutics, 2009; 6(1):246-54.
[10]  T. Elbayoumi and V. Torchilin, "Tumor-targeted nanomedicines: Enhanced anti-tumor efficacy in vivo of doxorubicin-loaded long-circulating liposomes modified with cancer-specific monoclonal antibody". Clinical Cancer Research, 2009; 15(6):1973-80.
[11]  T. Elbayoumi *, "Nano-drug delivery systems in cancer therapy: gains, pitfalls and considerations in DMPK", J Therapeutic Delivery, 2010 1(2): 215-219. Invited Editorial (*corresponding author).

Publications: Books/Book Chapters

[1]  T. Elbayoumi and V.Torchilin*, "Use of radiolabeled liposomes for Tumor Imaging", in "Nanoparticles in Biomedical Imaging", Bulte, JWM & Modo, M, Springer Verlag, London, Jan 2008 (102): 211-236.
[2]  T. Elbayoumi and V.Torchilin*, "Future trends in liposome research", in Method in Molecular Biology, Weissig, V, Humana Press, New Jersey, 2010;605:1-27.
[3]  T. Elbayoumi* and V.Torchilin, " Antibody-targeted liposomes and micelles for imaging applications", in Nanoimaging, Goins, B. and Phillips,W.T., Pan Stanford Publishing, Illinois, Sep 2011;109-128.
[4]  T. Elbayoumi* and V.Torchilin, "Tumor-specific nanomedicines: Antitumor antibody-modified doxorubicin-loaded liposomes", in Nanomedicine in Health and Disease, Preedy, V., Science Publishers(CRC press), New Hampshire, Jul 2011;336-355.